Withdrawal of phenobarbital and carbamazepine in epileptic patients: a preliminary neuropsychological report.
We systematically investigated the neuropsychological effects of controlled withdrawal of antiepileptic therapy with a battery of tests exploring intelligence, vigilance, attention, memory and sensori-motor performance. 16 patients without seizures for at least 2 years, 9 on therapy with phenobarbital (PB) and 7 with carbamazepine (CBZ), were examined 4 times over a period of 21 months. No significant correlation was found between drug levels and performance in the tests. The slight differences found between the PB and CBZ groups at full doses disappeared completely one year after withdrawal.
D000293:Adolescent; D000328:Adult; D002220:Carbamazepine / Q000009:adverse effects*; D003072:Cognition Disorders / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010634:Phenobarbital / Q000009:adverse effects*; D011596:Psychomotor Disorders / Q000139:chemically induced*; D013375:Substance Withdrawal Syndrome; D014145:Trail Making Test
D002220:Carbamazepine; D010634:Phenobarbital